GSA Capital Partners LLP Has $4.01 Million Holdings in Pfizer Inc. $PFE

GSA Capital Partners LLP lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 339.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 161,114 shares of the biopharmaceutical company’s stock after acquiring an additional 124,411 shares during the period. Pfizer makes up about 0.3% of GSA Capital Partners LLP’s investment portfolio, making the stock its 8th biggest position. GSA Capital Partners LLP’s holdings in Pfizer were worth $4,012,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Y Intercept Hong Kong Ltd bought a new position in Pfizer during the 3rd quarter valued at about $3,019,000. Kepler Cheuvreux Suisse SA bought a new position in Pfizer during the 3rd quarter valued at about $16,613,000. Money Concepts Capital Corp lifted its holdings in Pfizer by 29.9% during the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock valued at $6,325,000 after purchasing an additional 57,188 shares during the last quarter. Penn Davis Mcfarland Inc. lifted its holdings in Pfizer by 50.9% during the 4th quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock valued at $4,266,000 after purchasing an additional 57,777 shares during the last quarter. Finally, Mackenzie Financial Corp increased its position in Pfizer by 119.6% in the 3rd quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company’s stock valued at $79,157,000 after acquiring an additional 1,691,773 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.1%

Pfizer stock opened at $25.31 on Tuesday. The company’s 50 day simple moving average is $26.96 and its 200 day simple moving average is $26.20. Pfizer Inc. has a fifty-two week low of $22.64 and a fifty-two week high of $28.75. The firm has a market capitalization of $144.22 billion, a price-to-earnings ratio of 19.32 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same quarter in the previous year, the firm posted $0.92 earnings per share. The business’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer’s payout ratio is presently 131.30%.

Analysts Set New Price Targets

Several research firms have weighed in on PFE. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Guggenheim raised their price objective on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Barclays began coverage on shares of Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price objective for the company. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $28.84.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.